BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
IPO Year: 2020
Exchange: NASDAQ
Website: bioatla.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2024 | Buy → Neutral | H.C. Wainwright | |
| 9/15/2022 | $17.00 | Mkt Outperform | JMP Securities |
| 5/5/2022 | $35.00 → $5.00 | Outperform → Neutral | Credit Suisse |
| 3/21/2022 | $25.00 | Buy | H.C. Wainwright |
| 10/15/2021 | $68.00 | Buy | BTIG Research |
| 6/28/2021 | $75.00 | Buy | ROTH Capital |
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board. Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13D/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G/A - BioAtla, Inc. (0001826892) (Subject)
SC 13G - BioAtla, Inc. (0001826892) (Subject)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
4 - BioAtla, Inc. (0001826892) (Issuer)
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place Convention Center in Chicago, IL from April 25–30, 2025. Two abstracts accepted for poster presentation highlight Company's proprietary Conditionally Active Biologic (CAB) technologyDifferentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfor
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held online and at the McCormick Place Convention Center in Chicago, Illinois from May 30–June 3, 2025. Presentation Details: Title:Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neckAbstract Number:6048Session Type:
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster presentations at the upcoming European Lung Cancer Congress (ELCC) 2025 Scientific Committee and Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025, to be held in Paris, France from March 26–29, 2025 and in Scottsdale, AZ from March 27–29, 2025, respectively. Presentation Details: Venue:ELCC 2025Title:Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Pat
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call and Webcast Information Date: Thursday, March 27, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domes
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company ("BioAtla" or the "Company") focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.19 per share. Each warrant will be exercisable beginning six months after issuance and will expire 5.5
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antitumor activity observed across 9 different mKRAS variants Strong association of AXL expression by mKRAS NSCLC confirmed SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the tre
H.C. Wainwright downgraded BioAtla from Buy to Neutral
JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00
Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously
H.C. Wainwright initiated coverage of BioAtla with a rating of Buy and set a new price target of $25.00
BTIG Research resumed coverage of BioAtla with a rating of Buy and set a new price target of $68.00
ROTH Capital initiated coverage of BioAtla with a rating of Buy and set a new price target of $75.00
Credit Suisse resumed coverage of BioAtla with a rating of Outperform and set a new price target of $68.00
Credit Suisse resumed coverage of BioAtla with a rating of Outperform and set a new price target of $68.00
BTIG reiterated coverage of BioAtla with a rating of Buy and set a new price target of $87.00 from $47.00 previously
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2024 and provide business highlights. Conference Call and Webcast Information Date: Thursday, March 27, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla Fourth Quarter and Full-Year 2024 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domes
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the "FDA") regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all eight, first-line unresectable or metastatic melanoma patients with 4 responses including a complete response (CR), ongoing, with relatively low incidence and severity of immune-related adverse events;
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, November 7, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Third Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 343-4136 (domestic), (203) 518-9848 (internationa
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC) Phase 2 trial in NSCLC showed trend for improved overall survival among treated patients with tumors expressing mutated KRAS variants compared to KRAS wildtype; anti-tumor activity across multiple KR
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 8, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Thursday, August 8, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla Second Quarter 2024 Earnings Conference Call Dial-in Numbers: (800) 579-2543 (domestic), (785) 424-1789 (international)C
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CTLA-4 antibody) Phase 1 study progressing well, anticipate clearing dose-limiting toxicity (DLT) observation period with 1 gram (14.2 mg/kg) in 2Q 2024 and initial Phase 2 monotherapy data readout on track for 2Q 2024 and in combination with pembrolizumab in 2H 2024; anticipate FDA meeting for first-line, metastatic or unresectable, BRAF-mutated melanoma potential registrational trial in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC) initial 20
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights. Conference Call and Webcast InformationDate: Tuesday, May 14, 2024Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2024 Earnings Conference Call Dial-in Numbers: (877) 425-9470 (domestic), (201) 389-0878 (international)Conference
SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)
8-K - BioAtla, Inc. (0001826892) (Filer)
424B3 - BioAtla, Inc. (0001826892) (Filer)
EFFECT - BioAtla, Inc. (0001826892) (Filer)
S-3 - BioAtla, Inc. (0001826892) (Filer)
10-Q - BioAtla, Inc. (0001826892) (Filer)
8-K - BioAtla, Inc. (0001826892) (Filer)
SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)
DEFA14A - BioAtla, Inc. (0001826892) (Filer)
DEF 14A - BioAtla, Inc. (0001826892) (Filer)